hVIVO (HVO) CMD 2024 summary

Strategic direction and business development

• Targeting GBP 100 million revenue by 2028, representing a 12.7% CAGR, with 10-15% expected from M&A and a focus on organic growth and selective acquisitions.

• Shifted sales strategy to promote human challenge trials, leveraging a 90% market share in this niche.

• Broadened service offerings to include field studies, patient recruitment, laboratory support, and end-to-end infectious disease trial solutions.

• Expanded challenge agent portfolio, with 10 new agents manufactured in the past three years and more in development.

• Venn Life Sciences provides end-to-end drug development and regulatory services, supporting growth in non-challenge studies.

Financial performance and guidance

• Achieved GBP 35.6 million in H1 2024 revenue, a 31% year-on-year increase, with EBITDA margin rising to approximately 24%.

• Maintained full-year 2024 revenue guidance at GBP 62 million, with margin improvements expected as operations consolidate into the new facility.

• Weighted order book at GBP 71 million, slightly down due to revenue recognition and minor cancellations, but supported by a robust sales pipeline.

• Strong cash position of GBP 37.1 million as of June 2024, with no debt and a GBP 1.4 million dividend paid in May.

• Recruitment operations deliver the highest EBITDA margin percentage, with advertising costs held flat despite increased activity.

Facility and operational enhancements

• New Canary Wharf facility offers 50 inpatient beds, advanced negative pressure rooms, and BSL-3/CL3 labs, supporting a wider range of pathogens and transmission studies.

• Consolidated previous sites into a single location, increasing efficiency, headcount utilization, and operational agility.

• Laboratory capacity tripled, with flexible space for new contract types and automation initiatives to streamline workflows.

• Enhanced automation and workflow integration, including pneumatic sample transport and advanced LIMS systems.

• Improved participant and staff experience with modern amenities, infection control, and wellbeing spaces.